



Edgar Filing: SANOFI-AVENTIS - Form 6-K

| <u>Exhibit No.</u> | <u>Description</u>   |
|--------------------|--|
| Exhibit 99.1       | Press Release dated September 6, 2005, concerning program evaluating clopidogrel                                 |
| Exhibit 99.2       | Press Release dated September 9, 2005, concerning FDA advisory committee recommendation with respect to Exubera® |

2

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: September 9, 2005

SANOFI-AVENTIS

By: /s/ Patricia Kodyra  
Name: Patricia Kodyra  
Title: Associate Vice President  
Financial and Securities Law

3

---

**Exhibit List**

| <u>Exhibit No.</u> | <u>Description</u>   |
|--------------------|--|
| Exhibit 99.1       | Press Release dated September 6, 2005, concerning program evaluating clopidogrel                                 |
| Exhibit 99.2       | Press Release dated September 9, 2005, concerning FDA advisory committee recommendation with respect to Exubera® |

4

---